Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc. is a U.S.-based biopharmaceutical and technology holding company focused on acquiring, developing, and commercializing cell therapy technologies for cancer and other diseases. Through subsidiaries including Coeptis Therapeutics, Inc., SNAP Biosciences, Inc., and GEAR Therapeutics, Inc., it is shifting away from legacy generic drug activities toward innovative therapies and strategic development partnerships.

4

4.16

3.60

— Coeptis Therapeutics Holdings, Inc.
%
Cell therapy technologies60% Development and commercialization of cell-based therapies targeting cancer and other diseases.
Strategic partnerships and co-development20% Collaborations to advance autoimmune and oncology assets with external partners.
Legacy pharmaceutical products5% Previously commercialized 505(b)(2) anti-hypertension products that have since been abandoned.
Platform and holding company activities15% Subsidiary oversight, IP ownership, and corporate development activities supporting the portfolio.

The company’s end customers are healthcare providers, patients, and ultimately payers in oncology, autoimmune, and...

  • Oncology providers and treatment centersprimary

    Buy or adopt cell therapy solutions for cancer care because they need differentiated treatment options.

  • Strategic pharmaceutical partnersprimary

    Partner on development and commercialization to share risk, expertise, and market access.

  • Autoimmune therapy collaboratorssecondary

    Work with the company on co-development programs for immune-mediated diseases.

  • Healthcare distributors and marketing partnerssecondary

    Support launch and promotion of products where the company lacks a large direct commercial footprint.

The company states that its products and technologies are intended to be commercialized in the U.S...

  • •U.S. is the core operating and commercialization market
  • •Targets other major global markets through future commercialization
  • •No country-level revenue disclosure provided in the excerpts
  • •Regulatory and clinical execution are anchored in the United States
  • •International reach depends on partners and market approvals

Management is repositioning the company around innovative cell therapy and oncology-focused assets after exiting legacy...

01
Focus on cell therapy and oncology developmentmedium-term

These programs are the core of the company’s future value creation after exiting older product lines.

02
Expand strategic partnershipsshort-term

Partnerships provide technical capability, funding leverage, and commercialization support for a small biopharma platform.

03
Build a scalable holding-company platformmedium-term

A structured subsidiary base helps manage IP, development programs, and future acquisitions.

The company faces typical development-stage biopharma risks, including clinical failure, regulatory delays, and...

high

Clinical development failure

Cell therapy and oncology assets may not demonstrate safety or efficacy in trials.

Scope
Pipeline programs
Materiality
high
high

Regulatory approval delays

Biopharma products require extensive FDA and other regulatory review before commercialization.

Scope
U.S. and global commercialization plans
Materiality
high
high

Financing and dilution risk

Development-stage operations and professional fees can require repeated capital raises.

Scope
Corporate funding and operating runway
Materiality
high
medium

Partner and commercialization execution risk

The company relies on strategic partners for development and market access, reducing direct control.

Scope
Co-development and launch activities
Materiality
high
Reverse merger accounting
Historical financial statements and trend analysis
Stock-based compensation
Operating expenses and diluted share count
Warrant-related financing costs
General and administrative expense and non-operating items
Professional fee accruals
Quarterly expense volatility

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Grace Therapeutics, Inc.

GRCE · Pharmaceutical Preparations

Indaptus Therapeutics, Inc.

INDP · Pharmaceutical Preparations

: 28/04/2026